Tech Company Financing Transactions
Frontier Medicines Funding Round
Frontier Medicines closed a $88.5 million Series B funding round on 7/20/2021. Backers included RA Capital, Woodline Partners and ArrowMark Partners.
Transaction Overview
Company Name
Announced On
7/20/2021
Transaction Type
Venture Equity
Amount
$88,500,000
Round
Series B
Investors
RA Capital (Lead Investor) (Derek DiRocco)
Woodline Partners (Lead Investor)
Proceeds Purpose
The proceeds will be used to advance Frontier's wholly-owned pipeline of precision medicines against the most important drivers of cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 2nd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn't found a way to treat (or drug) with pharmaceutical interventions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Varma
Chief Financial Officer
Gregory Chow
Chief Scientific Officer
Kevin Webster
Chief Technical Officer
Johannes Hermann
Co-Founder
Daniel Nomura
Co-Founder
Roberto Zoncu
Vice President
Daniel Erlanson
Browse more venture capital transactions:
Prev: 7/20/2021: 75F venture capital transaction
Next: 7/20/2021: Julia Computing venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs